𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment

✍ Scribed by Philip Bonomi; Meryl Gale; Kendrith Rowland; Samuel G. Taylor IV; Sandra Purl; Salitha Reddy; Mai S. Lee; Alexander Phillips; C. Frederick Kittle; William Warren; L. Penfield Faber

Publisher
Elsevier Science
Year
1991
Tongue
English
Weight
745 KB
Volume
20
Category
Article
ISSN
0360-3016

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The value of combined-modality therapy i
The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer
✍ Steven E. Schild; Sumithra J. Mandrekar; Aminah Jatoi; William L. McGinnis; Phil πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 140 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. The objective of this study was to assess the value of combined‐modality therapy in elderly patients by comparing the differences in outcome between patients who received radiotherapy (RT) alone and patients who received RT plus chemotherapy for stage III nonsmall cell l

Combination versus sequential single-age
Combination versus sequential single-agent chemotherapy in the treatment of patients with advanced non-small cell lung cancer
✍ Niell, Harvey B. ;Griffin, John P. ;Hunter, Robert F. ;Meredith, Charlotte A. ;S πŸ“‚ Article πŸ“… 1989 πŸ› John Wiley and Sons 🌐 English βš– 716 KB

We have carried out a randomized phase Ill study in 105 patients with advanced nonsmall cell lung cancer, comparing a fourdrug cisplatin-mitomycin-based combination chemotherapy regimen t o sequential single-agent therapy. The combination chemotherapy regimen consisted of mitomycin C (10 mg/m2), vin